Evidence map›Paper›PMID 40248682›Full record

ArticleHepatology forum2025

Hepatic angiosarcoma in a patient treated with obeticholic acid for primary biliary cholangitis.

Arif A Arif, Subin Punnen, Michael Bleszynski, Owen Daniel R, Eric M Yoshida

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arif A ArifDepartment of Medicine, University of British Columbia, Vancouver BC, Canada.
Subin PunnenDepartment of Surgery, University of British Columbia, Vancouver BC, Canada.
Michael BleszynskiDepartment of Surgery, University of British Columbia, Vancouver BC, Canada.
Owen Daniel RDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC Canada.
Eric M YoshidaDepartment of Medicine, University of British Columbia, Vancouver BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease that can lead to cirrhosis and the development of hepatocellular carcinoma. PBC is not known to be associated with hepatic angiosarcoma. Second-line treatments for PBC, including obeticholic acid, have had less than a decade of clinical use. We present a case of a patient with PBC treated with obeticholic acid who subsequently developed hepatic angiosarcoma. The patient is now on active surveillance following resection of the angiosarcoma. The development of this rare and aggressive cancer should prompt closer post-marketing surveillance for obeticholic acid.

Indexed as

Hepatic angiosarcomaobeticholic acidprimary biliary cholangitis

Identifiers

PMID40248682
PMCPMC11999894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.